Autoimmune Encephalitis Misdiagnosis

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to discuss a new collaboration and a Mayo Clinic-led study focused on detecting DNA mutations. Later, Dr. Pritt welcomes Andrew McKeon, M.B., B.Ch., M.D., and Anastasia Zekeridou, M.D., Ph.D., co-directors of Mayo Clinic’s Neuroimmunology Laboratory, to discuss how they are advancing patient care.

Building on decades of leadership in autoimmune dysautonomia research, Mayo Clinic Laboratories has enhanced its dysautonomia antibody evaluation with a more sensitive, live cell-based flow cytometry method. The streamlined panel focuses on clinically relevant autoantibodies, providing physicians with actionable insights for diagnosis, prognosis, and treatment planning.

This microlearning reviews myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), with a focus on the 2023 International MOGAD Panel diagnostic criteria.